Healiva has announced a strategic collaboration with Lausanne University Hospital (CHUV). According to a press release, the Lugano-based biotech company will work with the hospital on the manufacture and approval of its proprietary autologous epidermal equivalent EpiDex.
“Joining forces with a recognized center of excellence in skin cell therapy marks a major milestone for the market launch plan for EpiDex,” says Healiva CEO and co-founder Dr Priyanka Dutta-Passecker. The press release explains that the partnership will give Healiva access to the manufacturing site of the CHUV Cell Production Centre (CHUV-CPC) and its unique expertise in the development of advanced therapy medicinal products. The two organizations will be able to pool their complementary skills in the treatment of chronic and acute wounds with cell therapy products.
EpiDex is made by taking cells from patient hair follicles and culturing them at the CHUV-CPC to produce small discs of autologous epidermis. These discs can then be applied to the wound in a simple, non-surgical procedure, where they promote the growth and healing of the skin.
“Healiva’s technology represents a significant opportunity to change the way we treat people with chronic wounds,” says Dr Jean-François Brunet, Director of CHUV-CPC. “We are fully committed to leveraging our experience in manufacturing technologies to support Healiva's manufacture of EpiDex.” ce/mm
Related news
Meet with an expansion expert
Our services are free of charge and include:
- Introduction to key contacts in industry, academia, and government
- Advice on regulatory framework, taxes, labor, market, and setting up a company
- Custom-made fact-finding visits, including office and co-working space